阿托伐他汀对冠心病患者脂蛋白(a)及CETP水平的影响

目的:分析阿托伐他汀对冠心病患者脂蛋白(a)、血清胆固醇酯转运蛋白(CETP)水平的影响及临床疗效。方法:将112例冠心病患者随机分为对照组与观察组,每组56例。对照组患者采用辛伐他汀治疗,观察组患者采用阿托伐他汀治疗。观察并比较两组患者治疗前后血清LP(a),CETP,超敏C-反应蛋白(hs-CRP)及脑钠肽(BNP)水平,冠状动脉血流储备、舒张期峰流速及收缩期峰流速变化,左心室后壁厚度(LVPWT)、左心室收缩末期内径(LVESD)及左心室舒张末期内径(LVEDD)情况,以及临床疗效。结果:治疗后,观察组LP(a),CETP,hs-CRP及BNP水平均低于对照组,差异有统计学意义(P0.05);观察组冠状动脉血流储备、舒张期峰流速、收缩期峰流速均高于对照组,差异有统计学意义(P0.05);观察组LVPWT、LVESD、LVEDD均低于对照组,差异有统计学意义(P0.05);观察组总有效率高于对照组,差异有统计学意义(P0.05);两组安全性比较,差异无统计学意义(P0.05)。结论:阿托伐他汀对冠心病患者的临床疗效比较明确,可下调LP(a)及血清CETP表达。

Effect of Atorvastatin on Serum Levels of Lipoprotein (a) and CETP in Patients with Coronary Heart Disease

ABSTRACT Objective: To analyze the effect of atorvastatin on the serum levels of lipoprotein (a) and cholesterol ester transfer protein (CETP) in patients with coronary heart disease and its clinical efficacy. Methods: 112 cases with coronary heart disease who were treated in our hospital were selected and randomly divided into the control group and the observation group, with 56 cases in each group. The patients in the control group were treated with simvastatin, while the patients in the observation group were treated with atorvastatin. Then the serum levels of LP (a), CETP, high sensitivity C-reactive protein (hs-CRP) and brain natriuretic peptide (BNP), and the coronary blood flow reserve, diastolic peak velocity and peak systolic velocity, left ventricular posterior wall thickness (LVPWT), left ventricular end systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD) and the clinical efficacy of two groups were observed and compared before and after the treatment. Results: After treatment, the serum levels of LP (a), CETP, hs-CRP and BNP in the observation group were lower than those of the control group, and the differences were statistically significant (P<0.05); The coronary artery flow reserve, diastolic peak flow velocity, systolic peak flow velocity, LVPWT, LVESD and LVEDD in the observation group were lower than those of the control group, and the differences were statistically significant (P<0.05); The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05); There was no statistically significant difference about the safety between the two groups (P>0.05). Conclusion: Atorvastatin has better clinical efficacy in the treatment of coronary heart disease, which can reduce the serum levels of LP (a) and CETP.